Cantor Fitzgerald Reiterates Overweight on Portage Biotech, Maintains $11 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Li Watsek has reiterated an Overweight rating on Portage Biotech (NASDAQ:PRTG) and maintained a price target of $11.
August 31, 2023 | 1:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Portage Biotech's stock rating has been reiterated as Overweight by Cantor Fitzgerald, with a maintained price target of $11.
The reiteration of an Overweight rating by a reputable analyst like Li Watsek from Cantor Fitzgerald is a positive signal for Portage Biotech. It suggests that the analyst believes the company's stock will outperform the market, which could lead to an increase in the stock's price. The maintained price target of $11 also indicates that the analyst sees potential for the stock's price to rise.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100